Lee Jennifer Kayden 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 14, 2025
Insider Transaction Report
Form 4
Lee Jennifer Kayden
EVP, Head of North America
Transactions
- Sale
Common Stock
2025-02-12$56.39/sh−600$33,834→ 4,813 total - Sale
Common Stock
2025-02-12$56.39/sh−1,205$67,950→ 3,598 total - Sale
Common Stock
2025-02-13$58.00/sh−1,205$69,890→ 2,393 total - Sale
Common Stock
2025-02-12$56.41/sh−10$564→ 4,803 total
Footnotes (2)
- [F1]The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.